

Oracle Life Sciences CancerMPact

Improving business outcomes through empowered decision making

At a glance

100% of the top 20 global pharmaceutical companies rely on Oracle Life Sciences CancerMPact to inform their business decisions

- Oracle Life Sciences CancerMPact modules are available individually or as a group by specific geographic region or tumor
- More than 30 tumor types are covered within the modules
- Custom tumor types or new geographies are available upon request

Oracle Life Sciences CancerMPact is an invaluable and comprehensive oncology decision support resource. It can be utilized for market analysis, strategic planning and identification of commercial opportunities.

How can Oracle Life Sciences CancerMPact help you?

Uncover cancer patient populations

- What are the current and future estimates of the number of patients by stage of disease and line of therapy?
- What are the best estimates of patient populations to utilize in product and market forecasts?
- What number and percentage of patients receive various treatment modalities, including surgery, radiation and chemotherapy?
- What are progression rates and survival statistics for patients by tumor types?
- What are the key drug agents/ regimens by cancer type and stage of disease?

Analyze physician decision making

- What are the key treatment modalities and drug agents/regimens utilized by cancer type, stage of disease and line of therapy?
- To what extent are patients' tumors tested for the presence or absence of a biomarker, by tumor type?
- How does treatment vary based on genetic differences and biomarker status?
- How does standard of care vary by geographic region?

Evaluate the competitive pivotal trial landscape

- What are potential changes in future treatment based on a critical evaluation of recently published or presented oncology clinical trial results and regulatory advances/setbacks?
- What are the most promising products in the development pipeline, and how do they fit into the competitive landscape?
- What are the key features/clinical endpoints of pivotal trials?
- What are key anticipated trends for each market, including new product introductions or label expansions?
- What are unmet needs for each cancer type?

Understand the early and late phase drug and trial landscape

- What new trials/agents have entered clinical development recently?
- What is the highest phase of development for a particular MOA?
- How long do early phase trials in a particular tumor take to complete?
- What developmental approaches are being explored in specific biomarkers or immunotherapy combinations?



Improving business outcomes through empowered decision making

Oracle Life Sciences CancerMPact is an invaluable and comprehensive oncology decision support resource. It can be utilized for market analysis, strategic planning and identification of commercial opportunities in the U.S., Western Europe, Japan and China. This resource is composed of cloud-based integrated modules: Patient Metrics (Patient Metrics – Core, Patient Metrics – Expanded Markets, PM Dashboards, and Biomarker Analysis), Treatment Architecture, Treatment Architecture Trends, and CancerLandscape.

1. Patient Metrics

Best-in-class cancer epidemiology and proprietary patient calculations for target markets.

Patient Metrics Core – U.S., Western Europe, Japan, China – combines epidemiologic data and analysis to estimate incidence (annual new cases of cancer) by stage; restaged 5-, 10-, or 15-year prevalence (annual surviving cancer patients from up to 15 years prior that accounts for progression to later stages); active disease (estimate of treatment-eligible patients by stage that does not include early-stage patients in remission); and treated patient populations by modality (surgery, radiation, drug therapy, etc.), drug regimens and drug agents.

Patient Metrics Expanded Markets – Combines epidemiologic data and analysis to estimate incidence (annual new cases of cancer) by stage; five-year prevalence (annual surviving cancer patients from up to five years prior; and treatable patients for up to 16 tumor types. Available for Argentina, Brazil, Canada, India, Mexico, Russia, South Korea, Taiwan and Turkey.

PM Dashboards – Interactive, multi-country views of the epidemiology and treatment of cancer, making comparisons across geographies, patients and tumors much easier. PM Dashboards features six interactive dashboards to allow you to more quickly and easily evaluate global trends in cancer epidemiology.

Biomarker Analysis – Expert analysis of key oncology biomarker segments. Biomarker Analysis is a global resource based on a thorough review of literature and recently published data that discusses the current and evolving oncology landscape with regard to biomarker segmentation rates and geographic, survival, ethnic, racial and gender differences.

2. Treatment Architecture

In-depth quantitative analysis of oncology drug and modality utilization across all cancer disease stages.

Treatment Architecture assesses the current clinical management of cancer patients by site and stage for all treatment modalities – including surgical, radiologic and systemic agents, as well as untreated patient populations. Treatment Architecture also provides pivotal clinical trial summaries to highlight the benchmark outcomes contributing to standard-of-care designations. Drug utilization is captured for all treatment settings and lines of therapy and by patient type in tumors where biomarkers have segmented the drug market.

3. Treatment Architecture Trends

Analytics for in-depth exploration of historical treatment patterns.

Treatment Architecture (TA) Trends allows for customized data exploration, powerful analytics, and impactful visualization of a wide variety of treatment data. TA Trends provides historical global treatment patterns allowing for analysis of the impact of market events on share and uptake of drugs and drug classes. A broad set of diagnostics, modality, drug, and outcomes data can be queried and filtered by stage, patient segment, drug technology, target, regimen, physician specialty, physician treatment setting and country.

4. Future Trends and Insights

Expert analysis of the changing oncology competitive landscape with focus on ongoing pivotal clinical trials.

Future Trends and Insights explores potential changes in treatment practices in the U.S., Western Europe and Japan based on a critical evaluation of recently published clinical data, regulatory advances/ setbacks and ongoing pivotal clinical trials. It identifies key trends in each tumor market, which can comprise new product introductions or label expansions of marketed products. It also assesses unmet needs for each cancer while continuously monitoring the competitive environment.

5. CancerLandscape

A visual, comprehensive overview of the oncology drug and trial landscape

CancerLandscape combines and standardizes U.S., EU, and Japan trial registries with other data sources to provide a visual and detailed understanding of the oncology trial landscape by company, tumor, drug and target. Users have the ability to filter on detailed clinical and commercial variables, make quick comparisons, uncover trends, and evaluate trial timing and enrollment. Gain insights about the oncology landscape in detail with a simple interface that is updated on a weekly basis. Clinical and scientific support is provided by the Oracle Life Sciences oncology support team.

The materials in this presentation pertain to Oracle Health, Oracle, Oracle Cerner, and Cerner Enviza which are all wholly owned subsidiaries of Oracle Corporation. Nothing in this presentation should be taken as indicating that any decisions regarding the integration of any EMEA Cerner and/or Enviza entities have been made where an integration has not already occurred.

